Abstract
Hypertension is a multi-etiological disease for which a multifactorial treatment approach has been advocated [1]. The multifactorial approach comprises lifestyle modification and/or administration of antihypertensive medications.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Trotman BW. Hypertension: a multietiological disease requires a multifactorial approach. J Assoc Acad Minor Phys 1995; 6(4):124.
Whitworth JA; World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21(11):1983–92.
Unger T, McInnes GT, Neutel JM, Böhm M. The role of olmesartan medoxomil in the management of hypertension. Drugs 2004; 64(24):2731–9.
Struijker-Boudier AJ, Ambrosioni E, Holzgreve H, et al. The need for combination antihypertensive therapy to reach target blood pressures: what has been learned from clinical practice and morbidity-mortality trials? Int J Clin Pract 2007; 61(9):1592–602.
Moser M. Is the stepped-care approach to the management of hypertension still appropriate? Chest 1985; 88(4):629.
Report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. A cooperative study. JAMA 1977; 237:255–61.
Neutel JM. The use of combination drug therapy in the treatment of hypertension. Prog Cardiovasc Nurs 2002; 17(2):81–8.
Fahey T, Schroeder K, Ebrahim S. Educational and organisational interventions used to improve the management of hypertension in primary care: a systematic review. Br J Gen Pract 2005; 55(520):875–82.
Fahey T, Schroeder K, Ebrahim S. Interventions used to improve control of blood pressure in patients with hypertension. Cochrane Database Syst Rev 2006; (4):CD005182.
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. US Department of Health and Human Services. NIH Publication No. 04-5230. Bethesda, MD: National Institutes of Health, August 2004.
Fuchs FD, Guerrero P, Gus M. What is next when the first blood pressure-lowering drug is not sufficient? Expert Rev Cardiovasc Ther 2007; 5(3):435–9.
Neutel JM. The role of combination therapy in the management of hypertension. Nephrol Dial Transplant 2006; 21(6):1469–74.
Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs 2002; 62:443–62.
Flack JM. Epidemiology and unmet needs in hypertension. J Manag Care Pharm 2007; 13(8 Suppl B):2–8.
Waeber B, Brunner HR. Rationale for the use of very-low-dose combinations as first-line treatment of hypertension. J Hypertens Suppl 2001; 19:S3–8.
Weir MR, Bakris GL. Combination therapy with renin–angiotensin-aldosterone receptor blockers for hypertension: how far have we come? J Clin Hypertens (Greenwich) 2008; 10:146–52.
Waeber B. Combination therapy with ACE inhibitors/angiotensin II receptor antagonists and diuretics in hypertension. Expert Rev Cardiovasc Ther 2003; 1:43–50.
Giles TD. Rationale for combination therapy as initial treatment for hypertension. J Clin Hypertens (Greenwich) 2003; 5(4 Suppl 3):4–11.
Weir MR. When antihypertensive monotherapy fails: fixed-dose combination therapy. South Med J 2000; 93(6):548–56.
Epstein M, Bakris G. Newer approaches to antihypertensive therapy. Use of fixed-dose combination therapy. Arch Intern Med 1996; 156:1969–78.
Ménard J. Critical assessment of combination therapy development. Blood Press Suppl 1993; 1:5–9.
Sica DA. Fixed-dose combination antihypertensive drugs. Do they have a role in rational therapy? Drugs 1994; 48:16–24.
Neutel JM, Saunders E, Bakris GL, et al., INCL USI VE Investigators. The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCL USI VE trial. J Clin Hypertens 2005; 7(10):578–86.
Kochar M, Guthrie R, Triscari J, Kassler-Taub K, Reeves RA. Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension. Am J Hypertens 1999; 12:797–805.
Mancia G, Omboni S, Grassi G. Combination treatment in hypertension: the VeraTran study. Am J Hypertens 1997; 10:153S–158S.
Coca A, Calvo C, Sobrino J, et al. Once-daily fixed-combination irbesartan 300 mg/hydrochlorothiazide 25 mg and circadian blood pressure profile in patients with essential hypertension. Clin Ther 2003; 25:2849 –64.
Neutel JM, Franklin SS, Oparil S, Bhaumik A, Ptaszynska A, Lapuerta P. Efficacy and safety of irbesartan/HCTZ combination therapy as initial treatment for rapid control of severe hypertension. J Clin Hypertens 2006; 8:850–7; quiz 858–9..
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2011 Springer Healthcare
About this chapter
Cite this chapter
Neutel, J. (2011). Historical Review of Combination Therapy. In: Combination Therapy in Hypertension. Springer Healthcare, Tarporley. https://doi.org/10.1007/978-1-908517-28-9_2
Download citation
DOI: https://doi.org/10.1007/978-1-908517-28-9_2
Published:
Publisher Name: Springer Healthcare, Tarporley
Print ISBN: 978-1-908517-25-8
Online ISBN: 978-1-908517-28-9
eBook Packages: MedicineMedicine (R0)